Barbara White
A5067962806- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammatory Myopathies and Dermatomyositis
- Dermatologic Treatments and Research
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Mast cells and histamine
- Social Work Education and Practice
- Eosinophilic Disorders and Syndromes
- Asthma and respiratory diseases
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Skin Diseases and Diabetes
- Intimate Partner and Family Violence
- Allergic Rhinitis and Sensitization
- LGBTQ Health, Identity, and Policy
- Urticaria and Related Conditions
- Connective Tissue Growth Factor Research
- Monoclonal and Polyclonal Antibodies Research
- Diagnosis and Treatment of Venous Diseases
- Autoimmune and Inflammatory Disorders Research
- Marriage and Sexual Relationships
- Psoriasis: Treatment and Pathogenesis
- Cannabis and Cannabinoid Research
Corbus Pharmaceuticals (United States)
2017-2025
Royal Stoke University Hospital
2021
California State University, Long Beach
2007-2018
University of California, Los Angeles
1995-2017
Epix Pharmaceuticals (United States)
2012
University of Maryland, Baltimore
1997-2008
The University of Texas at Austin
1994-2008
Johns Hopkins University
1904-2007
Georgetown University
2007
University of Maryland, College Park
1997-2007
We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence active alveolitis scleroderma-related interstitial disease.At 13 clinical centers throughout United States, we enrolled 158 scleroderma, restrictive physiology, dyspnea, inflammatory disease examination bronchoalveolar-lavage fluid, thoracic high-resolution computed tomography, or both. Patients received (<...
This criteria set has been approved by the American College of Rheumatology (ACR) Board Directors and European League Against Rheumatism (EULAR) Executive Committee as Provisional.This signifies that quantitatively validated using patient data, but it not undergone validation based on an external data set.All ACR/EULAR-approved sets are expected to undergo intermittent updates.The is independent, professional, medical scientific society which does guarantee, warrant, or endorse any...
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there no widely used definition of remission that stringent achievable and could be applied uniformly as outcome measure clinical trials. This work was undertaken to develop such a definition. Methods A committee consisting members the American College Rheumatology, European League Against Rheumatism, Outcome Measures Rheumatology Initiative met guide process review prespecified analyses from RA The...
The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year therapy, the duration benefit beyond was unclear.A second follow-up performed to determine if these effects persisted stopping treatment.A detailed analysis data obtained over two years study...
Background: Lung inflammation (alveolitis) may cause lung fibrosis in scleroderma. Objective: To determine whether cyclophosphamide treatment is associated with retention of function and improved survival scleroderma patients alveolitis. Design: Retrospective cohort study. Setting: Johns Hopkins University Maryland Scleroderma Center. Patients: 103 who had bronchoalveolar lavage or biopsy. Intervention: Cyclophosphamide therapy. Measurements: 1) Serial measurement forced vital capacity [FVC]...
Objective To test the hypothesis that systemic sclerosis (SSc) patients taking high-dose D-penicillamine (D-Pen) would have greater softening of skin, lower frequency renal crisis, and better survival than low-dose D-Pen. Methods Seventeen centers enrolled 134 SSc with early (≤18 months) diffuse cutaneous scleroderma into a 2-year, double-blind, randomized comparison D-Pen (750–1,000 mg/day) versus (125 mg every other day). All were followed up for mean ± SD 4.0 1.1 years to assess...
Abstract Objective To document disease activity and functional status in patients with scleroderma (systemic sclerosis [SSc]) Raynaud's phenomenon (RP) to determine the sensitivity change, reliability, ease of use, validity various outcome measures these patients. Methods Patients SSc moderate‐to‐severe RP participating a multicenter treatment trial completed daily diaries documenting frequency duration attacks recorded Condition Score (RCS). Mean scores for 2‐week periods prior baseline...
Objective To study the clinical implications of a skin thickness score ≥20 at first visit and softening sclerodermatous in cohort systemic sclerosis (SSc) patients with diffuse cutaneous scleroderma. Methods Skin visceral involvement were assessed 134 SSc scleroderma (mean ± SD duration 10 4 months) as they entered multicenter drug trial again 2 years followup. Advent mortality renal crisis (SRC) during followup 4.0 1.1 SD). Logistic linear regression used to examine relationship baseline...
Scleroderma is a chronic systemic disease that leads to fibrosis of affected organs. Transforming growth factor (TGF) beta has been implicated in the pathogenesis scleroderma. Smad proteins are signaling transducers downstream from TGF-beta receptors. Three families Smads have identified: (i) receptor-regulated Smad2 and -3 (R-Smads); (ii) common partner Smad4 (Co-Smad); (iii) inhibitory Smad6 -7 (I-Smads, part negative feedback loop). We investigated components for pathway activity...
Abstract Objective The reported frequency of scleroderma M01‐R renal crisis (SRC) in diffuse systemic sclerosis (SSc; scleroderma) is 15–20%. Early use angiotensin‐converting enzyme (ACE) inhibitors has markedly improved outcome. present analysis reexamines the prognostic factors for and outcome SRC a prospective cohort patients with early SSc. Methods We retrospectively evaluated SSc who participated High‐Dose Versus Low‐Dose D‐Penicillamine Diffuse trial. Patients cutaneous were enrolled...
Type I interferons (IFNs) appear to play a central role in disease pathogenesis systemic lupus erythematosus (SLE), making them potential therapeutic targets.Safety profile, pharmacokinetics, immunogenicity, pharmacodynamics and clinical activity of sifalimumab, an anti-IFNα monoclonal antibody, were assessed phase I, multicentre, randomised, double-blind, dose-escalation study with open-label extension adults moderately active SLE.received one intravenous dose sifalimumab (n=33 blinded...
To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and American College Rheumatology (ACR).The project followed EULAR standardized operating procedures, which use a three-step approach: 1) expert-based definition relevant research questions (November 2006); 2) systematic literature search 2006 May 2007); 3) expert consensus based results (May 2007). In addition, since this is...
<h3>Objective:</h3> To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and American College Rheumatology (ACR). <h3>Methods:</h3> The project followed EULAR standardised operating procedures, which use a three-step approach: (1) expert-based definition relevant research questions (November 2006); (2) systematic literature search 2006 May 2007); (3) expert consensus based results...
Objective To evaluate the efficacy and tolerability of an oral preparation iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon (RP) secondary to systemic sclerosis (scleroderma). Methods A multicenter, randomized, parallel-group, placebo-controlled double-blind study was performed at university community-based medical centers. Patients were randomly assigned receive either 50 µg iloprost orally twice daily or identical gelatin-coated capsule containing placebo for 6 weeks....
The adenovirus fiber protein is responsible for attachment of the virion to cell surface receptors. identity cellular receptor which mediates binding unknown, although there evidence suggesting that two distinct receptors interact with group C (adenovirus type 5 [Ad5]) and B (Ad3) adenoviruses. In order define determinants specificity, we have carried out a series competition experiments using recombinant native polypeptides from Ad5 Ad3 chimeric proteins in head domains were exchanged....
Abstract Objective Previous studies showed that etanercept treatment in patients with polyarticular‐course juvenile rheumatoid arthritis (JRA) provided rapid clinical improvement was sustained for up to 2 years. The goal of our study provide data on safety and efficacy after 4 years JRA. Methods Patients active JRA who participated an continued open‐label extension. Safety assessed by measuring rates serious adverse events (SAEs) infections. Efficacy using the American College Rheumatology...
Abstract Objective Lung transplantation is a viable, life‐saving intervention for several primary pulmonary disorders complicated by severe lung dysfunction. This study was undertaken to evaluate whether patients with systemic sclerosis (scleroderma), autoimmune rheumatic disorder, would receive similar benefit from this intervention. Methods Survival following examined at 2 university medical centers among 29 scleroderma as compared 70 idiopathic fibrosis (IPF) and 38 arterial hypertension...
Rationale: The presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis–associated interstitial lung disease.Objectives: To evaluate whether cellularity identifies distinct subsets and/or predicts cyclophosphamide responsiveness.Methods: Patients underwent baseline high-resolution computed tomography as part a randomized placebo-controlled trial versus placebo (Scleroderma Lung Study) determine effect...
Abstract Background Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses MEDI-528, humanized anti-IL-9 monoclonal antibody, in Methods Study 1: adults (18-65 years) with mild asthma received MEDI-528 (0.3, 1, 3 mg/kg) or placebo subcutaneously twice weekly 4 weeks. 2: (18-50 stable, moderate exercise-induced...
The objective of this study was to evaluate the relationship between blood mRNA, disease activity and treatment effects in a longitudinal patients with dermatomyositis (DM) or polymyositis (PM). In all, 24 DM PM were followed for up 6 years (mean 1.9 years) at 2-7 follow-up visits while receiving standard clinical care. Clinical data samples collected 80 patient used analysis cytokine-induced gene expression signaling pathways type 1 interferon (IFN), tumor necrosis factor-α, IL-1β,...
To assess the reliability and minimal clinically important differences (MCID) for FVC% predicted in Scleroderma Lung Study I II.
To assess the safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc).A randomized, double-blind, placebo-controlled, phase II study was conducted at 9 SSc clinics US. Adults with dcSSc ≤6 years' duration who were receiving stable standard-of-care treatment randomized to receive (n = 27) or placebo 15). Lenabasum doses 5 mg once daily, 20 twice daily for 4 weeks, followed by 8 weeks. Safety assessed weeks 4, 8, 12, 16.Adverse events (AEs) occurred 63% group 60%...
This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc).A multinational double-blind conducted 365 dcSSc who were randomized dosed 1:1:1 lenabasum 20 mg, 5 or placebo, each twice daily added background treatments, including immunosuppressive therapies (IST).The primary end point, American College Rheumatology combined response index (CRISS) at week 52 for mg day...